INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $909,127 | -16.3% | 17,453 | +1.8% | 0.01% | -11.1% |
| Q2 2023 | $1,085,874 | +7.8% | 17,149 | -7.8% | 0.01% | +12.5% |
| Q1 2023 | $1,007,298 | +63.5% | 18,602 | +59.7% | 0.01% | +60.0% |
| Q4 2022 | $616,253 | +41.7% | 11,645 | +24.5% | 0.01% | +25.0% |
| Q3 2022 | $435,000 | -12.7% | 9,357 | +7.3% | 0.00% | 0.0% |
| Q2 2022 | $498,000 | -13.2% | 8,719 | -7.1% | 0.00% | +33.3% |
| Q1 2022 | $574,000 | +42.8% | 9,383 | +22.0% | 0.00% | +50.0% |
| Q4 2021 | $402,000 | -56.4% | 7,691 | -66.6% | 0.00% | -33.3% |
| Q3 2015 | $922,000 | – | 23,014 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |